Bioventus Inc. Cl A

NAS: BVS

GO
/marketstate/country/us

Market open

 --Real time quotes

May 10, 2021, 2:04 p.m.

BVS
/zigman2/quotes/204270034/composite

$

14.71

Change

+0.05 +0.38%

Volume

Volume 33,295

Real time quotes

/zigman2/quotes/204270034/composite

Previous close

$ 14.65

$ 14.71

Change

+0.05 +0.38%

Day low

Day high

$14.27

$14.82

Open

52 week low

52 week high

$10.74

$19.51

Open

Company Description

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from a array of musculoskeletal conditions. It operates through four segments: Active Healing Therapies-U.S, Active Healing...

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from a array of musculoskeletal conditions. It operates through four segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on December 22, 2015 and is headquartered in Durham, NC.

Valuation

P/E Current

189.94

Efficiency

Revenue/Employee

458,801.00

Income Per Employee

15,023.00

Receivables Turnover

3.70

Total Asset Turnover

0.66

Liquidity

Current Ratio

1.73

Quick Ratio

1.49

Cash Ratio

0.71

Profitability

Gross Margin

70.38

Operating Margin

10.29

Pretax Margin

4.96

Net Margin

3.27

Return on Assets

2.18

Return on Equity

7.37

Return on Total Capital

9.33

Return on Invested Capital

3.11

Capital Structure

Total Debt to Total Equity

143.73

Total Debt to Total Capital

58.97

Total Debt to Total Assets

41.35

Long-Term Debt to Equity

131.81

Long-Term Debt to Total Capital

54.08

Officers and Executives

Name Age Officer Since Title
Mr. William A. Hawkins 66 2016 Chairman
Mr. Gregory O. Anglum 50 2016 Chief Accounting Officer
Mr. John E. Nosenzo - 2017 Chief Commercial Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/11/2021 Kenneth Michael Reali
Chief Executive Officer; Director
9,375   Acquisition at $13 per share. 121,875
02/11/2021 Gregory O. Anglum
SVP & General Counsel
6,000   Acquisition at $13 per share. 78,000
02/11/2021 Katrina J. Church
SVP & Chief Compliance Officer
2,500   Acquisition at $13 per share. 32,500
02/11/2021 Anthony D'Adamo
SVP & General Counsel
1,000   Acquisition at $13 per share. 13,000
02/11/2021 Alessandra Pavesio
SVP & Chief Science Officer
1,000   Acquisition at $13 per share. 13,000
02/11/2021 John E. Nosenzo
Chief Commercial Officer
500   Acquisition at $13 per share. 6,500
/news/latest/company/us/bvs

MarketWatch News on BVS

  1. Bioventus started at buy with $23 stock price target at Canaccord Genuity

    11:21 a.m. March 8, 2021

    - Tomi Kilgore

  2. Bioventus started at overweight with $17 stock price target at J.P. Morgan

    8:24 a.m. March 8, 2021

    - Tomi Kilgore

  3. Stocks Close at New Records as Investors Bet on Vaccines

    5:50 p.m. Feb. 12, 2021

    - Barron's Online

  4. 4 More Companies Make Their Market Debuts

    5:53 p.m. Feb. 11, 2021

    - Barron's Online

  5. Bumble Stock Gained 64% on First Day of Trading

    5:48 p.m. Feb. 11, 2021

    - Barron's Online

/news/nonmarketwatch/company/us/bvs

Other News on BVS

  1. Bioventus acquires Bioness for $45M up-front consideration

    5:52 p.m. March 30, 2021

    - Seeking Alpha

  2. 10-K: BIOVENTUS INC.

    4:15 p.m. March 26, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  3. Wall Street Breakfast: The Week Ahead

    8:16 a.m. March 7, 2021

    - Seeking Alpha

  4. Stocks To Watch: Spotlight On DraftKings, 5G Carriers And Roblox

    10:08 a.m. March 6, 2021

    - Seeking Alpha

  5. Bioventus - Interested And Questions At The Same Time

    8:12 a.m. Feb. 14, 2021

    - Seeking Alpha

  6. Bioventus Readies $125 Million IPO Effort

    7:51 p.m. Feb. 5, 2021

    - Seeking Alpha

At a Glance

Bioventus, Inc.

4721 Emperor Boulevard

Suite 100

Durham, North Carolina 27703

Phone

1 9194746700

Industry

Medical Equipment/Supplies

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$321.16M

Net Income

$10.52M

Employees

700.00

Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.